CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It develops pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.
IPO Year: 1997
Exchange: NASDAQ
Website: ctibiopharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/17/2022 | $13.00 | Outperform | SVB Leerink |
| 9/1/2022 | $13.00 | Buy | Jefferies |
| 7/7/2022 | $10.00 | Outperform | Cowen |
| 3/2/2022 | $4.00 → $5.00 | Market Outperform | JMP Securities |
| 3/2/2022 | $5.00 → $8.00 | Buy | Needham |
| 12/1/2021 | $6.00 → $5.00 | Buy | Needham |
| 8/9/2021 | $7.00 | Buy | BTIG Research |
4 - CTI BIOPHARMA CORP (0000891293) (Issuer)
4 - CTI BIOPHARMA CORP (0000891293) (Issuer)
4 - CTI BIOPHARMA CORP (0000891293) (Issuer)
4 - CTI BIOPHARMA CORP (0000891293) (Issuer)
4 - CTI BIOPHARMA CORP (0000891293) (Issuer)
4 - CTI BIOPHARMA CORP (0000891293) (Issuer)
4 - CTI BIOPHARMA CORP (0000891293) (Issuer)
4 - CTI BIOPHARMA CORP (0000891293) (Issuer)
4 - CTI BIOPHARMA CORP (0000891293) (Issuer)
4 - CTI BIOPHARMA CORP (0000891293) (Issuer)
15-12G - CTI BIOPHARMA CORP (0000891293) (Filer)
EFFECT - CTI BIOPHARMA CORP (0000891293) (Filer)
EFFECT - CTI BIOPHARMA CORP (0000891293) (Filer)
EFFECT - CTI BIOPHARMA CORP (0000891293) (Filer)
EFFECT - CTI BIOPHARMA CORP (0000891293) (Filer)
EFFECT - CTI BIOPHARMA CORP (0000891293) (Filer)
EFFECT - CTI BIOPHARMA CORP (0000891293) (Filer)
EFFECT - CTI BIOPHARMA CORP (0000891293) (Filer)
EFFECT - CTI BIOPHARMA CORP (0000891293) (Filer)
EFFECT - CTI BIOPHARMA CORP (0000891293) (Filer)
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF OR THE SOLICITATION OF AN OFFER TO BUY SECURITIES IN ANY JURISDICTION. STOCKHOLM, June 24, 2023 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO: SOBI) announced today that it has, through its indirect wholly owned subsidiary Cleopatra Acquisition Corp. (Cleopatra), successfully completed its tender offer to purchase all outstanding shares of common stock of CTI BioPharma Corp. (NASDAQ:CTIC) (CTI), at a price of USD 9.10 per sh
SEATTLE, May 30, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that it has cancelled the 2023 Annual Meeting of Stockholders (the "Annual Meeting") which was scheduled for June 21, 2023, and has withdrawn the proposals to have been submitted to stockholders at the Annual Meeting. The Annual Meeting has been cancelled due to the ongoing tender offer by Swedish Orphan Biovitrum AB (publ) (STO: SOBI) ("Sobi") to acquire all of the outstanding common stock of CTI pursuant to the Agreement and Plan of Merger, dated as of M
Transaction Price of $9.10 Per Share Represents Compelling 89% Premium to CTI's Closing Stock Price on May 9, 2023 SEATTLE, May 10, 2023 /PRNewswire/ -- CTI BioPharma (NASDAQ:CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that it has entered into a definitive agreement under which Swedish Orphan Biovitrum AB (STO: SOBI) ("Sobi"), a global healthcare leader in hematology, immunology and specialty care, will acquire CTI for $9.10 per share of common stock in an all-cash transaction, representing an implied equity value of approximately $1.7 billion. The transaction wi
SEATTLE, May 4, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employee's acceptance of employment with the company. The equity award was approved on May 3, 2023, in accordance with Nasdaq Listing Rule
SEATTLE, May 2, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employee's acceptance of employment with the company. The equity award was approved on May 1, 2023, in accordance with Nasdaq Listing Rule
SEATTLE, May 1, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that its first quarter 2023 financial results will be reported on Thursday, May 11, 2023, after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Registration for the live and archived webcast may be accessed on the CTI BioPharma website under the Investors & Media section: Events and Presentations. To participate via telephone, please register in a
– Data presentation on spleen volume reduction in patients with myelofibrosis also accepted for poster discussion – SEATTLE, May 1, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that two abstracts have been accepted for presentation at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023 in Chicago, IL. Presentation details are as follows: Title: Spleen volume reduction (SVR) predicts overall survival (OS) in myelofibrosis (MF) patients on pacritinib (PAC) but not best avai
SEATTLE, Wash., April 12, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that the management team will participate in two upcoming investor conferences in April 2023. 22nd Annual Needham Virtual Healthcare ConferenceType: Fireside ChatTuesday, April 18, 20233:45 p.m. ET (12:45 p.m. PT) Stifel 2023 Targeted Oncology Days (Virtual)Type: Corporate PresentationWednesday, April 26, 20231:00 p.m. ET (10:00 a.m. PT) A link to the live and archived webcast may be accessed on the CTI BioPharma website under the Investors & Media sectio
SEATTLE, April 10, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved on April 10, 2023, in accordance with Nasdaq Listin
SEATTLE, March 20, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to four new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved on March 20, 2023, in accordance with Nasdaq Listi
SVB Leerink initiated coverage of CTI BioPharma with a rating of Outperform and set a new price target of $13.00
Jefferies initiated coverage of CTI BioPharma with a rating of Buy and set a new price target of $13.00
Cowen initiated coverage of CTI BioPharma with a rating of Outperform and set a new price target of $10.00
JMP Securities reiterated coverage of CTI BioPharma with a rating of Market Outperform and set a new price target of $5.00 from $4.00 previously
Needham reiterated coverage of CTI BioPharma with a rating of Buy and set a new price target of $8.00 from $5.00 previously
Needham reiterated coverage of CTI BioPharma with a rating of Buy and set a new price target of $5.00 from $6.00 previously
BTIG Research initiated coverage of CTI BioPharma with a rating of Buy and set a new price target of $7.00
Stifel initiated coverage of CTI BioPharma with a rating of Buy and set a new price target of $5.50
FLORHAM PARK, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks, an executive with deep experience in the commercialization of novel immuno-oncology therapies, has led the successful launch of numerous hematology and cancer therapies at large pharmaceutical and biotech companies, including Kite Pharma, Inc. (now part of Gilead Sciences, Inc.), Amgen Inc., and Genentech, Inc. (now part of Roche Holdings, Inc.). "It is with great pleasure we welcome Diane to the Cel
SEATTLE, Aug. 24, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks has overseen the launch of numerous hematology and cancer therapies at large pharmaceutical and biotech companies, including Kite Pharma, Amgen, and Genentech. "Diane is an accomplished leader with considerable experience driving the successful planning, launch, and commercialization of new medicines in hematology and oncology," said Laurent Fischer, M.D., Chairman of the Board of CTI Biopharma. "We are pleased to have Diane join CTI's Board of Directors at this pivotal time as we advance our JAK2/IRAK-1 inhibitor pacritinib towards a po
SC 13D/A - CTI BIOPHARMA CORP (0000891293) (Subject)
SC 13G - CTI BIOPHARMA CORP (0000891293) (Subject)
SC 13G - CTI BIOPHARMA CORP (0000891293) (Subject)
SC 13G/A - CTI BIOPHARMA CORP (0000891293) (Subject)
SC 13G/A - CTI BIOPHARMA CORP (0000891293) (Subject)
SC 13G/A - CTI BIOPHARMA CORP (0000891293) (Subject)
SC 13G - CTI BIOPHARMA CORP (0000891293) (Subject)
SC 13D/A - CTI BIOPHARMA CORP (0000891293) (Subject)
SC 13D/A - CTI BIOPHARMA CORP (0000891293) (Subject)
SC 13D/A - CTI BIOPHARMA CORP (0000891293) (Subject)
Transaction Price of $9.10 Per Share Represents Compelling 89% Premium to CTI's Closing Stock Price on May 9, 2023 SEATTLE, May 10, 2023 /PRNewswire/ -- CTI BioPharma (NASDAQ:CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that it has entered into a definitive agreement under which Swedish Orphan Biovitrum AB (STO: SOBI) ("Sobi"), a global healthcare leader in hematology, immunology and specialty care, will acquire CTI for $9.10 per share of common stock in an all-cash transaction, representing an implied equity value of approximately $1.7 billion. The transaction wi
SEATTLE, May 1, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that its first quarter 2023 financial results will be reported on Thursday, May 11, 2023, after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Registration for the live and archived webcast may be accessed on the CTI BioPharma website under the Investors & Media section: Events and Presentations. To participate via telephone, please register in a
– Growing physician awareness and usage of VONJO® (pacritinib) drove quarterly double-digit revenue growth – – VONJO® net product revenue exceeded year-end goal with a total of $54 million for 2022 and $21.1 million in the fourth quarter, a 16% increase compared to the third quarter – – ASH 2022 oral presentation featured new data on pacritinib's ACVR1 inhibition and anemia benefit in myelofibrosis patients – – Management to host webcast and conference call at updated time today at 8:30 a.m. ET – SEATTLE, March 6, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for bloo
SEATTLE, Feb. 23, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that its fourth quarter and full year 2022 financial results will be reported on Monday, March 6, 2023, after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Registration for the live and archived webcast may be accessed on the CT
– VONJO® (pacritinib) net product revenue of $18.2 million in the third quarter, a 48% increase compared to the second quarter – – Increase in sales reflects strong growth in new patient starts – – Oral presentation of new data on pacritinib's ACVR1 inhibition and anemia benefit in myelofibrosis patients at ASH 2022 – – Management to host conference call today at 4:30 p.m. ET – SEATTLE, Nov. 7, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported its financial results for the third quarter ended September 30, 2022. "In the third quarter, CTI continued to make strong progress with the U.S. commercial launch of VONJO, delivering net revenue of $18.2 million, a 48% increase in
SEATTLE, Oct. 27, 2022 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ:CTIC) today announced that management plans to report its third quarter 2022 financial results on Monday, November 7, 2022, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a conference call and webcast to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT). To participate via telephone, please register in advance using this link: https://register.vevent.com/register/BI1dc7f17da2ae4ce8ba0e490c169604ac. Upon registration, telephone participants will receive a confirmation email detailing how to join the conf
– VONJO® (pacritinib) net product revenue of $12.3 million in the second quarter – – Management to host conference call today at 4:30 p.m. ET – SEATTLE, Aug. 8, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported its financial results for the second quarter ended June 30, 2022. "CTI continues to make substantial headway with the U.S. commercial launch of VONJO, as we work to become the market leader in the treatment of cytopenic myelofibrosis. In the second quarter, we have performed well generating net product revenue of $12.3 million," said Adam Craig, President and Chief Executive Officer of CTI BioPharma. "With a differentiated profile, VONJO is a simple, safe and effec
– Company Also Announces Participation in the BTIG Biotechnology Conference and the Stifel Biotech Summer Summit – SEATTLE, Aug. 1, 2022 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its second quarter 2022 financial results on Monday, August 8, 2022, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a conference call and webcast to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT). To access the live call by phone please dial (888) 317-6003 (domestic) or (412) 317-6061 (international); the conference ID is 0078819. A l
– Strong U.S. commercial launch of VONJO™ (pacritinib) underway following accelerated FDA approval for the treatment of adult patients with Myelofibrosis and Thrombocytopenia – – VONJO (pacritinib) net product revenue of $2.3 million in less than one month following launch, exceeding initial Company expectations – – VONJO included as recommended first- and second-line treatment in NCCN® Clinical Practice Guidelines in Oncology for Myeloproliferative Neoplasms – – Abstracts accepted at ASCO 2022 and EHA 2022 in June – – Management to host conference call today at 4:30 p.m. ET – SEATTLE, May 12, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported its financial results for the
SEATTLE, April 28, 2022 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ:CTIC) today announced that management plans to report its first quarter 2022 financial results on Thursday, May 12, 2022, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a conference call and webcast to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT). To access the live call by phone please dial (877) 735-2860 (domestic) or (602) 563-8791 (international); the conference ID is 7291915. A
JMP Securities analyst Reni Benjamin maintains CTI BioPharma (NASDAQ:CTIC) with a Market Perform.
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70. Here’s the latest list of major overbought players in this sector. Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Cerevel Therapeutics appointed Susan Altschuller, as Chief Financial Officer. The company’s stock has a 52-week high of $41.4
Upgrades According to Macquarie, the prior rating for Lufax Holding Ltd (NYSE:LU) was changed from Underperform to Outperform. For the fourth quarter, Lufax Holding had an EPS of $0.05, compared to year-ago quarter EPS of $0.19. The current stock performance of Lufax Holding shows a 52-week-high of $7.05 and a 52-week-low of $1.26. Moreover, at the end of the last trading period, the closing price was at $1.64. Barrington Research upgraded the previous rating for Warner Bros. Discovery Inc (NASDAQ:WBD) from Market Perform to Outperform. For the first quarter, Warner Bros. Discovery had an EPS of $0.44, compared to year-ago quarter EPS of $0.69. The current stock performance of Warner Bros
SVB Leerink analyst Andrew Berens downgrades CTI BioPharma (NASDAQ:CTIC) from Outperform to Market Perform and lowers the price target from $13 to $9.1.
Analysts have provided the following ratings for CTI BioPharma (NASDAQ:CTIC) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 1 0 0 Last 30D 0 0 1 0 0 1M Ago 1 1 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 1 0 0 0 These 5 analysts have an average price target of $8.82 versus the current price of CTI BioPharma at $8.925, implying downside. Below is a summary of how these 5 analysts rated CTI BioPharma over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock This current average repre
Stifel analyst Benjamin Burnett downgrades CTI BioPharma (NASDAQ:CTIC) from Buy to Hold and raises the price target from $8.1 to $9.1.
Investors are on the hunt for undervalued, underfollowed and emerging stocks and retail traders have countless methods at their disposal to uncover new information. For some, this may be overwhelming. Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks each week that are just under the surface and warrant attention. The index layers editorial commentary to help make sense of why these stocks should be of interest and whether investors and casual readers should watch them. Here is a look at the Benzinga Stock Whisper Index for the week of May 11, 2023. CTI Biopharma Corp (NASDAQ:CTIC): Shares of biopharmaceutical company CT
Upgrades According to Evercore ISI Group, the prior rating for Phathom Pharmaceuticals Inc (NASDAQ:PHAT) was changed from In-Line to Outperform. In the first quarter, Phathom Pharmaceuticals showed an EPS of $0.89, compared to $1.07 from the year-ago quarter. The current stock performance of Phathom Pharmaceuticals shows a 52-week-high of $13.44 and a 52-week-low of $5.84. Moreover, at the end of the last trading period, the closing price was at $12.43. For Baidu Inc (NASDAQ:BIDU), OTR Global upgraded the previous rating of Mixed to Positive. Baidu earned $2.21 in the fourth quarter, compared to $1.82 in the year-ago quarter. At the moment, the stock has a 52-week-high of $160.88 and a 52
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its first quarter. • Addex Therapeutics (NASDAQ:ADXN) is projected to report earnings for its first quarter. • Fiverr Intl (NYSE:FVRR) is expected to report quarterly earnings at $0.24 per share on revenue of $87.66 million. • Teekay (NYSE:TK) is likely to report earnings for its first quarter. • Teekay Tankers (NYSE:TNK) is likely to report quarterly earnings at $4.38 per share on revenue of $243.55 million. • Pharming (NASDAQ:PHAR) is likely to report earnings for its first quarter. • Algonq
JMP Securities analyst Reni Benjamin downgrades CTI BioPharma (NASDAQ:CTIC) from Market Outperform to Market Perform.